• 1
    Katayama I, Kohno Y, Akiyama K et al. Japanese guideline for atopic dermatitis. Allergol Int 2011; 60:205220.
  • 2
    Wollina U. Cutaneous T cell lymphoma: update on treatment. Int J Dermatol 2012; 51:10191036.
  • 3
    Sokolowska-Wojdylo M, Baranska-Rybak W, Cegielska A, Trzeciak M, Lugowska-Umer H, Gniadecki R. Atopic dermatitis-like pre-Sezary syndrome: role of immunosuppression. Acta Derm Venereol 2011; 91:574577.
  • 4
    Hanafusa T, Azukizawa H, Kitaba S et al. Diminished regulatory T cells in cutaneous lesions of thymoma-associated multi-organ autoimmunity: a newly described paraneoplastic autoimmune disorder with fatal clinical course. Clin Exp Immunol 2011; 166:164170.
  • 5
    Roncador G, Brown PJ, Maestre L et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunogenet 2005; 35:16811691.
  • 6
    Rensing-Ehl A, Gaus B, Bruckner-Tuderman L, Martin SF. Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Exp Dermatol 2007; 16:1321.
  • 7
    Neish C, Charlry M, Jegasothy B, Tharp M, Deng JS. Proliferation cell nuclear antigen and soluble interleukin 2 receptor levels in cutaneous T cell lymphoma: correlation with advanced clinical diseases. J Dermatol Sci 1994; 8:1117.
  • 8
    Vonderheid EC, Zhang Q, Lessin SR et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38:207220.
  • 9
    Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci 2011; 64:16.
  • 10
    Miyagaki T, Sugaya M, Suga H et al. Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels. J Eur Acad Dermatol Venereol 2013; 27:1924.